SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Policy
Makary, Prasad Lay Out Mission for FDA in Journal Kennedy Called ‘Corrupt’
FDA Commissioner Marty Makary and CBER Director Vinay Prasad published an article in JAMA on Tuesday outlining the FDA’s priorities, including accelerating cures and the rapid deployment of artificial intelligence.
June 11, 2025
 · 
3 min read
 · 
Heather McKenzie
Pictured: Bristol Myers Squibb office in California
Deals
BMS Expands Radiopharma Presence With $1.35B Biobucks Deal for Philochem
Instead of homing in on PSMA—currently the most validated target in prostate cancer—BMS and Philochem will instead collaborate on an early-stage molecule that binds to a novel marker called ACP3.
June 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Fund raising Capital Donation. Funds Support Concept. Fundraising. Collecting donations in jar.
Funding
SpliceBio Nabs $135 Million Series B To Advance Protein Splicing Medicines
The company’s intein-based technology is initially aimed at Stargardt disease, a type of macular degeneration.
June 11, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Government
AMA Calls for Senate Probe Into RFK Jr. After Removal of CDC Vaccine Advisors
The American Medical Association is also urging an “immediate reversal” of the HHS Secretary’s decision to oust all 17 members of the CDC’s vaccine advisory board.
June 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Composite photo collage of serious man walk look wristwatch hand chief point out dismissal failure late isolated on painted background.
Layoffs
After Axing Diabetes Asset, Vertex Lays Off 140 Staff
The layoffs will heavily affect Vertex’s operations in Rhode Island, where the biotech will consolidate three facilities into one.
June 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Cardiovascular disease
Insmed ‘Blows Away Expectations’ With Positive Data for Inhaled Hypertension Therapy
Guggenheim Partners called Insmed’s Phase IIb readout “impressive across the board,” with an efficacy profile that positions TPIP to be best-in-class in pulmonary arterial hypertension.
June 11, 2025
 · 
2 min read
 · 
Tristan Manalac
Money dollar rolled up with pills flowing out isolated on blue background, high costs of expensive medication concept. Copy space.
Obesity
Novo Ups Obesity Ante With $800M+ Deep Apple Pact for Oral, Non-Incretin Drugs
For $812 million, Novo Nordisk will enlist Deep Apple to discover and develop a non-incretin therapy for obesity, months after the Danish pharma’s amylin efforts underwhelmed investors.
June 11, 2025
 · 
3 min read
 · 
Tristan Manalac
Crowdfunding concept with money icon and human hands in retro 80s collage mixed media vector illustration. Idea for financing business project, funding, philanthropy, cooperation, bank credit and startup development.
Weight loss
Lilly Bites Again in $650M Muscle-Preserving Treatment Pact With Juvena
The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to develop long-acting versions of molecules against GLP-1 and other incretins.
June 11, 2025
 · 
1 min read
 · 
Annalee Armstrong
Podcast
RFK Axes CDC Vaccine Advisors; Metsera’s Weight Loss Win; FDA Supports CGT
HHS Secretary Robert F. Kennedy Jr. made waves this week, firing the remaining members of the CDC’s Advisory Committee on Immunization Practices; Metsera’s amylin drug produced weight loss of 8.4% at 36 days; and FDA leaders gathered last week to discuss the future of cell and gene therapy, a sector that has been in turmoil since the ousting of CBER Chief Peter Marks.
June 11, 2025
 · 
1 min read
 · 
Heather McKenzie
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS